Citations

Clear

3942 citation(s) found for "To, Van".

MR elastography: Principles, guidelines, and terminology
Manduca, Armando , Bayly, Philip V. , Kolipaka, Arunark , Royston, Thomas J. , Sack, Ingolf , Beers, Bernard E. Van , Sack, Ingolf , Manduca, A , Ehman, Richard L. , Sinkus, Ralph

Mayo Clinic

Magnetic Resonance in Medicine | December 10, 2020 | Volume: 85 | Issue: 5 | Pages: 2377-2390

10.1002/mrm.28627 | PMID 33296103 Get It

Magnetic resonance elastography (MRE) is a phase contrast–based MRI technique that can measure displacement due to propagating mechanical waves, from which material properties such as shear modulus can be calculated. Magnetic resonance elastography can be thought of as quantitative, noninvasive palpation. It is increasing in clinical importance, has become widespread in the diagnosis and staging of liver fibrosis, and additional clinical applications are being explored. However, publications have reported MRE results using many different parameters, acquisition techniques, processing methods, and varied nomenclature. The diversity of terminology can lead to confusion (particularly among clinicians) about the meaning of and interpretation of MRE results. This paper was written by the MRE Guidelines Committee, a group formalized at the first meeting of the ISMRM MRE Study Group, to clarify and move toward standardization of MRE nomenclature. The purpose of this paper is to (1) explain MRE terminology and concepts to those not familiar with them, (2) define “good practices” for practitioners of MRE, and (3) identify opportunities to standardize terminology, to avoid confusion.
CERTL reduces C16 ceramide, amyloid-β levels and inflammation in a model of Alzheimer's disease
Luo, Qian , Stevens, Jo , Giovagnoni, Caterina, Bode, Gerard H., Hobo, Barbara , Scheithauer, Anna-Lena, Hove, Daniël L.A. van den, Verhaagen, Joost , Bieberich, Erhard , Crivelli, Simone Mwenda , Kruining, Daan van , Hoedt, Sandra den , Walter, Jochen , Mulder, Monique T , Exley, Christopher , Mold, Matthew John , Mielke, Michelle M. , Vries, Helga E. de , Wouters, Kristiaan , Berkeš, Dušan , Ledesma, María Dolores , Losen, Mario , Martínez‐Martínez, Pilar

Mayo Clinic

No container title available | December 9, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-42740/v2 Get It

Abstract Background: Dysregulation of ceramide and sphingomyelin levels have been suggested to contribute to the pathogenesis of Alzheimer’s disease (AD). Ceramide transfer proteins (CERTs) are ceramide carriers, crucial for ceramide and sphingomyelin balance in cells. Extracellular forms of CERTs co-localize with amyloid-β (Aβ) plaques in AD brains. To date, the significance of these observations for the pathophysiology of AD remains uncertain.Methods: The plasmid expressing CERTL, the long isoform of CERTs, was used to study the interaction of CERTL with amyloid precursor protein (APP) by co-immunoprecipitation and immunofluorescence in HEK cells. The recombinant CERTL protein was employed to study interaction of CERTL with amyloid-β (Aβ), Aβ aggregation process in presence of CERTL, and the resulting changes in Aβ toxicity in neuroblastoma cells. CERTL was overexpressed in neurons by adeno associated virus (AAV) in a familial mouse model of familial AD (5xFAD). Ten weeks after transduction, animals were challenged with behavior tests for memory, anxiety and locomotion. At week twelve, brains were investigated for sphingolipid levels by mass spectrometry, plaques and neuroinflammation by immunohistochemistry, gene expression and/or immunoassay.Results: Here, we report that CERTL, binds to APP, modifies Aβ aggregation and reduces Aβ neurotoxicity in vitro. Furthermore, we show that intracortical injection of AAV, mediating the expression of CERTL, decreases levels of ceramide d18:1/16:0 and increases sphingomyelin levels in the brain of male 5xFAD mice. CERTL in vivo over-expression has a mild effect on animal locomotion, decreases Aβ formation and modulates microglia by decreasing their pro-inflammatory phenotype.Conclusion: Our results demonstrate a crucial role of CERTL in regulating ceramide levels in the brain, in amyloid plaque formation and neuroinflammation, thereby opening research avenues for therapeutic targets of AD and other neurodegenerative diseases.
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease
Rhee, Frits van , Oksenhendler, Éric , Srkalović, Gordan , Voorhees, Peter M. , Lim, Megan S. , Ide, Makoto , Parente, Sophia A. T. , Schey, Stephen, Streetly, Matthew , Wu, David , Brandstadter, Joshua D. , Munshi, Nikhil C. , Bowne, Wilbur B. , Elenitoba‐Johnson, Kojo S.J. , Lechowicz, Mary Jo , Chandrakasan, Shanmuganathan , Pierson, Sheila K. , Greenway, Amy D, Yoshizaki, Kazuyuki , Chadburn, Amy , van Rhee, Frits , Ide, Makoto , Lim, Megan S , Chandrakasan, Shanmuganathan , Dispenzieri, Angela , Wong, Raymond , Maillard, Ivan P. , Fosså, Alexander , Nasta, Sunita , Kurzrock, Razelle , Uldrick, Thomas S. , Casper, Corey , Fajgenbaum, David C.

Mayo Clinic

Blood Advances | December 9, 2020 | Volume: 4 | Issue: 23 | Pages: 6039-6050

10.1182/bloodadvances.2020003334 | PMID 33284946 Get It

Abstract Castleman disease (CD) includes a group of rare and heterogeneous disorders with characteristic lymph node histopathological abnormalities. CD can occur in a single lymph node station, which is referred to as unicentric CD (UCD). CD can also involve multicentric lymphadenopathy and inflammatory symptoms (multicentric CD [MCD]). MCD includes human herpesvirus-8 (HHV-8)–associated MCD, POEMS-associated MCD, and HHV-8−/idiopathic MCD (iMCD). The first-ever diagnostic and treatment guidelines were recently developed for iMCD by an international expert consortium convened by the Castleman Disease Collaborative Network (CDCN). The focus of this report is to establish similar guidelines for the management of UCD. To this purpose, an international working group of 42 experts from 10 countries was convened to establish consensus recommendations based on review of treatment in published cases of UCD, the CDCN ACCELERATE registry, and expert opinion. Complete surgical resection is often curative and is therefore the preferred first-line therapy, if possible. The management of unresectable UCD is more challenging. Existing evidence supports that asymptomatic unresectable UCD may be observed. The anti–interleukin-6 monoclonal antibody siltuximab should be considered for unresectable UCD patients with an inflammatory syndrome. Unresectable UCD that is symptomatic as a result of compression of vital neighboring structures may be rendered amenable to resection by medical therapy (eg, rituximab, steroids), radiotherapy, or embolization. Further research is needed in UCD patients with persisting constitutional symptoms despite complete excision and normal laboratory markers. We hope that these guidelines will improve outcomes in UCD and help treating physicians decide the best therapeutic approach for their patients.
Long‐term deprivation of ovarian hormones via ovariectomy alters functional connectivity, brain neurochemistry and white matter integrity in a mouse model of Alzheimer's disease
Voncken, Rick , Sarwari, Zahra, Yadav, Garima, Anckaerts, Cynthia, Langbeen, A., Leysen, Valérie, Hamaide, Julie, Daans, Jasmijn, Guglielmetti, Caroline , Roßner, Steffen , Kara, Firat , Belloy, Michaël E. , Yadav, Garima, Shah, Disha , Jacobs, Jules, Bols, Peter E.J. , Audekerke, Johan Van , Kantarci, Kejal , Prévot, Vincent , Ponsaerts, Peter , Linden, Annemie Van der , Verhoye, Marleen

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S4 | Pages: No page available

10.1002/alz.037354 Get It

AbstractBackgroundThe abrupt loss of ovarian hormones before menopause, induced by oophorectomy, has been associated with accelerated aging, multimorbidity, and Alzheimer’s disease (AD). We investigated the impact of prolonged loss of ovarian hormones on AD progression in a transgenic mouse model of amyloid pathology using in vivo diffusion tensor MRI, resting‐state functional MRI (rsfMRI) and spectroscopy (MRS).MethodFemale 3.5‐month‐old TG2576 (TG) (N=27) and wild‐type (WT) (N=27) mice were ovariectomized (TGOVX) or sham‐operated (TGSHAM). When they became 18‐month‐old, 1‐H MRS (ROIs: hypothalamus, hippocampus, and cerebral cortex), DTI and rsfMRI was performed. ROI based analysis was performed on rsfMRI and DTI (Fractional anisotropy (FA), axial diffusivity (AxD), mean diffusivity, and radial diffusivity). The brain samples were then evaluated by histology and ELISA to assess Aβ load and activated glial cells. The loss of ovarian hormones via OVX was validated with elevated plasma luteinizing hormone level: OVX>SHAM (p<0.05). Two‐way ANOVA and post‐hoc (Student’s‐t) tests were used for statistical analysis. P values were adjusted for multiple comparisons (FDR‐p).ResultThe multimodel imaging data showed that there was a significant increase in taurine and total creatine (markers for inflammation and energy metabolism) in the hypothalamus, decrease in FA and AxD (markers for white matter integrity) in the white matter regions, and decrease in the functional connectivity between the prefrontal cortex and the hippocampus and dorsal and ventral hippocampus regions (a neural marker of network activity and integrity) (FDR‐p <0.05 (Figure 1)) in TGOVX mice compared to TGSHAM mice (post‐hoc t‐test). rsFMRI showed a significant increase in rsfMRI connectivity in WTOVX mice compared to WTSHAM mice. Complementary histological (and ELISA) analysis revealed no differences in Aβ load (plaque and soluble) and activated glial cells between the TG groups.ConclusionThe MRI results suggest that inflammatory response was elevated, energy metabolism was disrupted and white matter and network integrity decreased after prolonged ovarian hormone loss. These MRI results support other data from human and animal studies suggesting that abrupt hormonal changes associated with premenopausal removal of ovaries may increase the risk factors of AD, and accelerate the disease progression by causing abnormalities in brain structure, function and metabolism.
Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab
Clifford, David B., Coalier, Kelley A., Fagan, Anne M. , Farlow, Martin R. , Mills, Susan , Salloway, Stephen , Santacruz, Anna , Wang, Guoqiao , Snider, B. Joy, Mummery, Catherine J. , Surti, Ghulam M., Hannequin, Didier , Jiménez‐Velázquez, Ivonne Z. , Dyck, Christopher H. van , Gauthier, Serge , Galasko, Doug, Jayadev, Suman , Formaglio, Maïté, Clarnette, Roger, Pariente, Jérémie , Dubois, Bruno, Andersen, Scott W. , Holdridge, Karen C. , Mintun, Mark A., Sims, John R. , Yaari, R. , Baudler, Monika, Doody, Rachelle S., Fontoura, Paulo , Kerchner, Geoffrey A. , Team, DIAN‐TU Study, Bateman, Randall J. , Aschenbrenner, Andrew J. , Benzinger, Tammie L.S. , Cruchaga, Carlos , Goate, Alison , Gordon, Brian A. , Hassenstab, Jason , Jack, Clifford R. , Koeppe, Robert A. , McDade, Eric , Morris, John C. , Snyder, Peter J. , Xiong, Chengjie , Wallon, David , Berman, Sarah , Lah, James J. , Roberson, Erik D. , Honig, Lawrence S. , Sánchez‐Valle, Raquel , Brooks, William S. , Masters, Colin L. , Brosch, Jared R. , Hsiung, Ging‐Yuek Robin , Masellis, Mario , Dubois, Bruno, Pasquier, Florence , Delmar, Paul , Team, DIAN‐TU Study

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S9 | Pages: No page available

10.1002/alz.041129 Get It

AbstractBackgroundAlzheimer’s disease (AD) prevention trials aim to intervene prior to significant neuronal loss, brain damage, and symptom onset to delay or slow cognitive decline. In dominantly inherited AD (DIAD), mutation carriers develop symptomatic AD at predictable ages with near 100% penetrance. In 2012, the Dominantly Inherited Alzheimer Network Trials Unit Adaptive Prevention Trial (DIAN‐TU APT) platform launched a double‐blind, randomized, placebo‐controlled, parallel group trial of two anti‐amyloid‐beta monoclonal antibodies with two different antigenic targets, gantenerumab and solanezumab (NCT01760005). The DIAN‐TU scientific development, implementation of the first AD prevention trial, trial challenges and opportunities, including dose escalation, and top‐line results will be presented.MethodDIAN was established in 2008 in response to a call from the National Institute of Aging to establish a network to study DIAD and enable future clinical trials. Successive breakthroughs in understanding disease processes enabled the launch of the DIAN‐TU adaptive prevention trial, a global adaptive platform trial supporting testing multiple drugs in parallel. The DIAN‐TU partners include patients and families at risk for DIAD, global academic researchers, the NIH, Alzheimer’s Association, philanthropic supporters, the DIAN‐TU Pharma Consortium, and pharmaceutical companies with drugs being tested. Important milestones include developing a platform to enable a comprehensive efficient treatment trial for this rare population, adding tau PET as part of AMP AD, adapting dosing mid‐trial and extending the original biomarker trial to continue randomized dosing to test a cognitive endpoint until the last patient reaches 4 years, developing a disease progression statistical model and inclusion of DIAN observational data to increase the power to determine drug effects.ResultThe primary and key secondary outcomes of the DIAN‐TU trial will be presented for each therapy in the context of targeting amyloid‐beta at pre‐clinical and clinically symptomatic stages of disease.ConclusionThese results inform about AD hypotheses, timing of treatment and the prospect of slowing, or preventing AD in DIAD and sporadic AD.
Gantenerumab in‐depth outcomes
Salloway, Stephen , Clifford, David B., Coalier, Kelley A., Fagan, Anne M. , Farlow, Martin R. , Mills, Susan , Santacruz, Anna , Wang, Guoqiao , Snider, B. Joy, Mummery, Catherine J. , Surti, Ghulam M., Hannequin, Didier , Jiménez‐Velázquez, Ivonne Z. , Dyck, Christopher H. van , Gauthier, Serge , Galasko, Doug, Jayadev, Suman , Formaglio, Maïté, Clarnette, Roger, Pariente, Jérémie , Dubois, Bruno, Baudler, Monika, Doody, Rachelle S., Fontoura, Paulo , Kerchner, Geoffrey A. , Team, DIAN‐TU Study, Bateman, Randall J. , Aschenbrenner, Andrew J. , Benzinger, Tammie L.S. , Cruchaga, Carlos , Goate, Alison , Gordon, Brian A. , Hassenstab, Jason , Jack, Clifford R. , Koeppe, Robert A. , McDade, Eric , Morris, John C. , Snyder, Peter J. , Xiong, Chengjie , Wallon, David , Berman, Sarah , Lah, James J. , Roberson, Erik D. , Honig, Lawrence S. , Sánchez‐Valle, Raquel , Brooks, William S. , Masters, Colin L. , Brosch, Jared R. , Hsiung, Ging‐Yuek Robin , Masellis, Mario , Dubois, Bruno, Pasquier, Florence , Delmar, Paul , Team, DIAN‐TU Study

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S9 | Pages: No page available

10.1002/alz.038049 Get It

AbstractBackgroundGantenerumab is a humanized anti‐amyloid‐beta monoclonal antibody in clinical development for the treatment of several stages of Alzheimer disease (AD). Gantenerumab was evaluated in a phase 2/3 clinical trial program designed to evaluate its efficacy in autosomal dominant AD based on a combination of clinical and biomarker evidence.MethodThe study enrolled both mutation carriers (n=69 with 3:1 randomization of treatment (n=52) vs placebo (n=17)) and non‐carriers (n=28, all on placebo) from 15 years before to 10 years after the expected age of onset inclusive. Patients were both asymptomatic (CDR 0 and MMSE >25) and symptomatic (CDR 0.5‐1 and MMSE >16). There were 41 asymptomatic and 28 symptomatic mutation carriers. The initial dose of gantenerumab was 225 mg monthly administered subcutaneously. The dose was titrated to 1200 mg/month following a protocol amendment based on the increased amyloid lowering seen at higher doses in the gantenerumab program in symptomatic AD. The treatment duration was a minimum of 4 years (range 48‐80 months). The primary outcome was change from baseline in the DIAN‐TU multivariate cognitive endpoint. Secondary clinical outcomes included the DIAN‐TU cognitive composite, Cogstate multivariate cognitive endpoint, CDR SB, and time to CDR progression of >0.5 points. Change from baseline in amyloid PET was the primary biomarker outcome. Other biomarker outcomes included MRI, tau PET, CSF amyloid, tau and phosphotau, and CSF and plasma neurofilament light (NfL). Safety outcomes including ARIA were compared between drug and placebo groups.ResultWe will report change from baseline on the DIAN‐TU multivariate cognitive endpoint, DIAN‐TU cognitive composite, CDR‐SB and other secondary efficacy endpoints. We expect significant lowering on amyloid PET with PIB and florbetapir based on the results from recent anti‐amyloid antibodies, including Gantenerumab, in sporadic AD. We will also present the results of change in other key imaging and fluid biomarkers. The frequency, duration, and severity of ARIA will be reported and compared with studies in sporadic AD.ConclusionThis clinical trial was designed to inform future for ADAD and will provide new insights on the role of amyloid reduction in both pre‐symptomatic and clinical AD.
Solanezumab in‐depth outcomes
Farlow, Martin R. , Clifford, David B. , Coalier, Kelley A., Fagan, Anne M. , Gordon, Brian A., Mills, Susan , Morris, John C., Salloway, Stephen P., Santacruz, Anna , Wang, Guoqiao , Snider, B. Joy, Mummery, Catherine J. , Surti, Ghulam M., Hannequin, Didier , Jiménez‐Velázquez, Ivonne Z. , Dyck, Christopher H. van , Gauthier, Serge , Galasko, Doug, Jayadev, Suman , Formaglio, Maïté, Clarnette, Roger, Pariente, Jérémie , Dubois, Bruno, Andersen, Scott W. , Holdridge, Karen C. , Mintun, Mark A., Sims, John R. , Yaari, Roy, Team, DIAN‐TU Study, Bateman, Randall J. , Aschenbrenner, Andrew J. , Benzinger, Tammie L.S. , Cruchaga, Carlos , Goate, Alison , Gordon, Brian A. , Hassenstab, Jason , Jack, Clifford R. , Koeppe, Robert A. , McDade, Eric , Morris, John C. , Snyder, Peter J. , Xiong, Chengjie , Wallon, David , Berman, Sarah , Lah, James J. , Roberson, Erik D. , Honig, Lawrence S. , Sánchez‐Valle, Raquel , Brooks, William S. , Masters, Colin L. , Brosch, Jared R. , Hsiung, Ging‐Yuek Robin , Masellis, Mario , Dubois, Bruno, Pasquier, Florence , Yaari, R. , Team, DIAN‐TU Study

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S9 | Pages: No page available

10.1002/alz.038028 Get It

AbstractBackgroundSolanezumab is a monoclonal antibody targeting soluble forms of β‐amyloid protein important in the pathogenesis of Alzheimer’s disease (AD). Three previous 18‐month double‐blind placebo‐controlled trials of low‐dose solanezumab in late‐onset sporadic AD found inconsistent benefits on cognitive and functional assessments. Dominantly‐inherited mutation‐associated AD subjects both before and after onset of symptoms form an ideal population to study potential benefits of solanezumab therapy.MethodMutation‐carrying asymptomatic (CDR 0, N=41) or mildly symptomatic (CDR 0.5 – 1, N=28) patients were treated for a minimum of 4 years and up to 7 years in a double‐blind 3 to 1 active versus placebo randomized clinical trial that measured disease progression by clinical, neuropsychological and biomarker evaluations. The trial was initiated with a dose of 400 mg every 4 weeks and escalated to 1600 mg when low dose trials in sporadic AD did not meet their primary endpoints. The primary cognitive outcome measure was DIAN‐MCE, composed of Delayed Recall Score of the International Shopping List Test, the Delayed Recall score of the Logical Memory IIa subtest from the Wechsler Memory Scale‐Revised, the Digit Symbol Substitution Test total score from the WAIS‐R and the MMSE total score. Secondary outcomes included a battery of other cognitive and functional measures. The study was powered to detect delay of cognitive disease progression in the DIAN‐MCE. Biomarkers include imaging modalities (volumetric MRI, FDG, amyloid and Tau PET). CSF markers included β‐amyloid, Tau and PhosphoTau species. NfL was measured in both CSF and plasma. The study used a pre‐specified Bayesian multivariate disease progression model, which included dynamic borrowing of control subjects from the DIAN Observational study.ResultThe topline efficacy, safety and biomarker results will be reported.ConclusionThis study provides the first test of targeting soluble abeta forms in DIAD. It addresses the efficacy of early initiation of higher doses of solanezumab targeting soluble forms of amyloid as a disease modifying therapy. While these results are specific to DIAD, they have the potential to inform the application of anti‐amyloid therapy in sporadic AD.
Systemic Inflammatory Response Syndrome Is Associated With Increased Mortality Across the Spectrum of Shock Severity in Cardiac Intensive Care Patients
Jentzer, Jacob C. , Lawler, Patrick R. , Diepen, Sean van , Henry, Timothy D. , Menon, Venu , Baran, David A. , Džavík, Vladimír, Barsness, Gregory W. , Holmes, David R. , Jentzer, Jacob C , Baran, David A , Lawler, Patrick , van Diepen, Sean , Kashani, Kianoush

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | December 7, 2020 | Volume: 13 | Issue: 12 | Pages: No page available

10.1161/circoutcomes.120.006956 | PMID 33280435 Get It

Background: The systemic inflammatory response syndrome (SIRS) frequently occurs in patients with cardiogenic shock and may aggravate shock severity and organ failure. We sought to determine the association of SIRS with illness severity and survival across the spectrum of shock severity in cardiac intensive care unit (CICU) patients. Methods: We retrospectively analyzed 8995 unique patients admitted to the Mayo Clinic CICU between 2007 and 2015. Patients with ≥2/4 SIRS criteria based on admission laboratory and vital sign data were considered to have SIRS. Patients were stratified by the 2019 Society for Cardiovascular Angiography and Interventions (SCAI) shock stages using admission data. The association between SIRS and mortality was evaluated across SCAI shock stage using logistic regression and Cox proportional-hazards models for hospital and 1-year mortality, respectively. Results: The study population had a mean age of 67.5±15.2 years, including 37.2% women. SIRS was present in 33.9% of patients upon CICU admission and was more prevalent in advanced SCAI shock stages. Patients with SIRS had higher illness severity, worse shock, and more organ failure, with an increased risk of mortality during hospitalization (16.8% versus 3.8%; adjusted odds ratio, 2.1 [95% CI, 1.7–2.5]; P <0.001) and at 1 year (adjusted hazard ratio, 1.4 [95% CI, 1.3–1.6]; P <0.001). After multivariable adjustment, SIRS was associated with higher hospital and 1-year mortality among patients in SCAI shock stages A through D (all P <0.01) but not SCAI shock stage E. Conclusions: One-third of CICU patients meet clinical criteria for SIRS at the time of admission, and these patients have higher illness severity and worse outcomes across the spectrum of SCAI shock stages. The presence of SIRS identified CICU patients at increased risk of short-term and long-term mortality. Further study is needed to determine whether systemic inflammation truly drives SIRS in this population and whether patients with SIRS respond differently to supportive therapies for shock.
A Sound Method for Axillary Vein Access
Zyl, Martin van , Deshmukh, Abhishek

Mayo Clinic

No container title available | December 5, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.160722565.59453010/v1 Get It

Ultrasound guided venous access Is important to minimize pneumothorax and unnecessary incisions in patients undergoing device implant.